[ad_1]
- Ireland temporarily halted use of the AstraZeneca Covid-19 vaccine on Sunday.
- The launch was stopped after Norway reported cases of severe blood clotting after inoculation.
- Ireland is the latest EU country to suspend the use of the AstraZeneca vaccine, after Austria, Italy and Denmark.
- Visit the Insider home page for more stories.
Ireland became the latest country on Sunday to suspend use of the AstraZeneca Covid-19 vaccine after more reports came out from Norway of severe blood clotting in some recipients.
According to the Irish Times, Ireland’s National Advisory Committee on Immunization (CANI) deputy chief medical officer Ronan Glynn said that while the launch has been temporarily postponed, “it has not been concluded that there is any link between the AstraZeneca vaccine and these cases. “.
However, CANI said it would expect “more reassuring data” and would put a pause in the administration of vaccines as a precaution. The CANI will meet again this week to discuss the suspension of the vaccine.
The BBC reported that more than 110,000 doses of the AstraZeneca vaccine have already been administered in Ireland. This brings the vaccine count to 20% of all Covid-19 vaccines administered to date in the country.
There have been more than 226,000 COVID cases in Ireland and 4,534 deaths.
Denmark, Iceland, Norway, Bulgaria and Thailand have discontinued use of the vaccine jointly developed by AstraZeneca and the University of Oxford.
Insider also reported that five EU countries (Austria, Estonia, Lithuania, Luxembourg and Latvia) had stopped using a specific batch of the AstraZeneca vaccine after the death of a vaccinated person. The batch consisted of 1 million doses that were shipped to 17 EU countries.
In a statement to CNN, AstraZeneca has defended the vaccine, saying there were no quality problems with the vaccine and “there is no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia” for those who received it. .
An AP report said the World Health Organization and the European Union drug regulator had echoed AstraZeneca’s statement, saying there was no link between receiving the Covid-19 vaccine and the increased risk of clotting. posterior bloodstream.
The AstraZeneca vaccine has been granted emergency use in more than 50 countries,
AstraZeneca’s vaccine has received a conditional marketing authorization or emergency use in more than 50 countries, but an emergency use authorization has not yet been issued in the US.
